rct
    2014

    Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial

    Abbas Z, Yakoob J, Jafri W, Ahmad Z, Azam Z, Usman MW, Shamim S, Islam M

    Published in European Journal of Gastroenterology & Hepatology

    Key Findings

    S. boulardii improved quality of life scores and reduced pro-inflammatory cytokines in diarrhoea-predominant IBS, though core symptom scores improved in both arms.

    Conclusions

    Possible anti-inflammatory benefit in IBS-D with limited symptom advantage over placebo.

    Limitations

    Single centre; small sample; short duration.

    Supplements Studied

    S. boulardii improved quality of life scores and reduced pro-inflammatory cytokines in diarrhoea-predominant IBS.

    Related Health Concerns

    IBS (Irritable Bowel Syndrome)

    Study Details

    Year:2014
    Sample Size:72
    Duration:6 weeks
    Quality Score:5/10

    Access Study

    View on DOIOriginal Source

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.